KLRA News & Events

Kailera Therapeutics priced 39.06M shares at $16.00. The deal size was increased and priced at the high end of the range. Kailera is an advanced clinical-stage biotechnology company that says it is "focused on elevating the next era of obesity care."

Kailera Therapeutics priced 39.06M shares at $16.00. The deal size was increased to 39.06M shares from 33.3M and priced at the high end of the $14.00-$16.00 range.

Kailera Therapeutics priced 39.06M shares at $16.00. The deal size was increased to 39.06M shares from 33.3M and priced at the high end of the $14.00-$16.00 range. JPMorgan, Jefferies, Leerink, TD Cowen and Evercore ISI are acting as joint book running managers for the offering. Kailera is an advanced clinical-stage biotechnology company that says it is "focused on elevating the next era of obesity care."

The deal size was increased to 39.06M shares from 33.3M and priced at high end of $14.00-$16.00 range. JPMorgan, Jefferies, Leerink, TD Cowen and Evercore ISI are acting as joint book running managers for the offering.